Crestchem
- Market cap
- ₹ 46 Cr.
- P/E
- 15.8x
- P/B
- 4.76x
- 52-week range
- 73.01 – 185
- ROE
- 31%
- ROCE
- 43.4%
- Debt / equity
- 0
- Sector
- Chemicals & Petrochemicals
- Industry
- Specialty Chemicals
- Listed on
- BSE
About
Crestchem Limited is an India-based company, which is engaged in the business of manufacturing, marketing and exporting products derived from the newly developed field of nutraceutical ingredients, emerging from the conventional chemical, food, and pharmaceutical fields. The Company is primarily involved in the manufacturing of nutrition-chemical products. The Company is also focused on manufacturing / marketing of three kinds of product groups in the nutritional chemical field, including medium chain triglycerides (MCTs), lactose free products, and oil's and fat's water-soluble powders. The lactose free products include lactose free skimmed milk powder (LFSMP), spray dried, and complete and balanced nutrition formulations (based on the lactose free concept). The oils and fats in powder form include spray dried (water-soluble oils and fat powders), high olic sunflower oil powder, palm oil powder, coconut oil powder, aromatic oil powder on dairy base material, and dairy cream powder.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Specialty Chemicals: 130 companies →Crestchem against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)15.8 against a typical 25.8: cheaper than most peers (1st = cheapest).41st of 129
- Sales growth+82.5% against a typical +25.9% from a year earlier.11th of 112
- Profit growth+180% against a typical +42.4% from a year earlier.18th of 102
- Share price, 3 months+14.5% against a typical −2.7%.24th of 118
- Size₹ 45.7 Cr. market value against a typical ₹ 359.6 Cr. (1st = largest).105th of 126
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4 | 7 | 6 | 5 | 8 | 5 | 7 | 5 | 7 | 7 | 10 | 9 |
| Expenses | 4 | 6 | 5 | 4 | 7 | 4 | 7 | 5 | 7 | 6 | 9 | 8 |
| Operating Profit | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 |
| OPM % | 9.1% | 16.7% | 15.1% | 14.5% | 16.3% | 13.5% | 8.3% | 7.2% | 8.5% | 11.3% | 13.7% | 12.9% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 2 | 1 |
| Tax % | 26.1% | 28.9% | 28% | 27.7% | 28.3% | 27.4% | 15.3% | 25.5% | 25.7% | 25.8% | 30.6% | 27.9% |
| Net Profit | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 |
| EPS in Rs | 1.13 | 3.03 | 2.2 | 2 | 3.33 | 1.73 | 2.03 | 1.17 | 1.8 | 2.4 | 3.67 | 3.27 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 72%
- 5 Years
- 31%
- 3 Years
- 21%
- TTM
- 36%
- 10 Years
- 41%
- 5 Years
- 37%
- 3 Years
- 58%
- TTM
- 35%
- 10 Years
- 29%
- 5 Years
- 17%
- 3 Years
- 27%
- TTM
- —
- 10 Years
- 35%
- 5 Years
- 39%
- 3 Years
- 41%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Crestchem | ₹ 150.00 | ₹ 46 Cr. | 15.8x | 4.8x | 31% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.9x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 74x | 11.6x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 76.4x | 20.2x | 27.1% | 15.3% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.3x | 4.3x | 19.7% | 18.5% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 28x | 3.4x | 11.8% | 13.7% |
Management
- Dipak Narendraprasad Patel
- Managing Director, Executive Chairman of the Board
- Nitinkumar Shantilal Shah
- Chief Financial Officer, Compliance Officer, Company Secretary
Prices are delayed and for information only. Nothing on this page is investment advice.